Amiodarone reduces the incidence of atrial fibrillation after coronary artery bypass grafting  by Yagdi, Tahir et al.
Cardiopulmonary
Support and
Physiology
Amiodarone reduces the incidence of atrial fibrillation
after coronary artery bypass grafting
Tahir Yagdi, MD, Sanem Nalbantgil, MD, Fatih Ayik, MD, Anil Apaydin, MD, Fatih Islamoglu, MD, Hakan Posacioglu, MD,
Tanzer Calkavur, MD, Yuksel Atay, MD, and Suat Buket, MD
Dr Yagdi
See related editorial on page
1202.
Objective: The purpose of this study was to evaluate the safety and efficacy of
postoperative administration of prophylactic amiodarone in the prevention of new-
onset postoperative atrial fibrillation in patients undergoing coronary artery bypass
grafting.
Methods: In this prospective study 157 patients were randomly divided into two
groups: 77 patients (amiodarone group) received intravenous amiodarone in a dose
of 10 mg/kg/d for postoperative 48 hours. On postoperative day 2 oral amiodarone
was started with a dose of 600 mg/d for 5 days, 400 mg/d for the following 5 days,
and 200 mg/d for 20 days, and 80 patients received placebo (control group).
Results: Preoperative patient characteristics and operative variables were similar in
the two groups. Postoperative atrial fibrillation occurred in 8 patients (10.4%)
receiving amiodarone and in 20 (25.0%) patients receiving placebo (P  .017).
Duration of atrial fibrillation was 12.8  4.8 hours for the amiodarone group
compared with 34.7  28.7 hours for the control group (P  .003). The maximum
ventricular rate during atrial fibrillation was slower in the amiodarone group than in
the control group (105.9 19.1 beats per minute and 126.0 18.5 beats per minute,
respectively, P  .016). The two groups had a similar incidence of complication
other than rhythm disturbances (20.8% vs 20.0%, P  .904). Amiodarone group
patients had shorter hospital stays than that of control group patients (6.8 1.7 days
vs 7.8  2.9 days, P  .014). The in-hospital mortality was not different between
two groups (1.3% vs 3.8, P  .620).
Conclusions: Postoperative intravenous amiodarone, followed by oral amiodarone,
appears to be effective in the prevention of new-onset postoperative atrial fibrilla-
tion. It also reduces ventricular rate and duration of atrial fibrillation after coronary
artery bypass grafting. It is well tolerated and decreases the length of hospital stay.
New-onset atrial fibrillation (AF) is a frequent clinical problem andoccurs in up to one third of patients undergoing coronary arterybypass grafting (CABG), with a peak incidence on postoperativedays 2 to 3.1-4 Advanced age and withdrawal of preoperative-blockers, together with postoperative sympathetic activationand a history of preoperative paroxysmal supraventricular ar-
rhythmia, seem to play a major role in the development of AF.5 Although postop-
erative AF usually does not result in long-term sequelae, it often increases length
and cost of hospital stay due to hemodynamic compromise or thromboembolic
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complications.6 The loss of contribution of normal atrial
contraction on cardiac performance may result in hemody-
namic deterioration during the postoperative period.
Over the years, different regimens have been proposed to
prevent postoperative AF. Several pharmacologic agents
such as digoxin, -blockers, calcium channel blockers,
quinidine, magnesium, and sotalol have been used to pre-
vent the occurrence of AF after CABG.7-12 Many of these
agents have been disappointing and none of them has been
uniformly accepted as a drug of choice.
Amiodarone, a class III antiarrhythmic drug with antiad-
renergic properties, has been reported to be effective in
converting AF to sinus rhythm and in the treatment of
refractory AF.13,14 Although considered to be a class III
antiarrhythmic, amiodarone also has class I, II, and IV
actions, which give it a unique pharmacologic and antiar-
rhythmic profile.15 It can be taken orally after a high-dose
preloading.16 Preoperative oral amiodarone has been shown
to decrease the occurrence of AF after cardiac surgery.17 In
this prospective study, we aimed to assess the efficacy of
short-course intravenous amiodarone followed by oral ther-
apy in the prevention of new-onset AF after CABG.
Patients and Methods
Patient Selection
This prospective trial evaluated 157 patients (mean age 60.2 9.3,
range 36-78 years) who underwent elective CABG at Ege Univer-
sity Hospital from October 2000 to November 2001. There were
121 men and 36 women. All of the patients were in sinus rhythm
and had a baseline corrected QT interval of 440 ms or less.
Exclusion criteria were refusal of consent; the presence of preop-
erative chronic AF; history of paroxysmal AF; myocardial infarc-
tion less than 3 weeks before surgery; second- or third-degree
atrioventricular block; sick sinus syndrome; need for temporary or
permanent pacemaker; preoperative use of certain interacting
drugs (phenytoin, cyclosporine, cholestyramine, cimetidine, or
class I and class III antiarrhythmic drugs); history of amiodarone
side effects; use of amiodarone in the year preceding the operation;
heart rate less than 60 beats/min at rest; an initial systolic blood
pressure of less than 100 mm Hg; redo coronary artery bypass
surgery; concomitant operations such as valve replacement and
aneurysmectomy; thyroid disease; asthma; chronic obstructive pul-
monary disease; chronic renal failure (serum creatinine greater
than 1.9 mg/dL); or liver function test results greater than 2 times
normal. The Institutional Review Board approved the study, and
all patients gave written informed consent for participation in the
study the day before surgery.
Study Protocol
The patients were randomly assigned in a double-blind fashion to
treatment with amiodarone or placebo. In the amiodarone group,
intravenous amiodarone was begun postoperatively, within 2 hours
of entering the cardiovascular surgical intensive care unit (ICU).
An intravenous infusion without a loading dose was given for 48
hours at a dose of 10 mg/kg per day. On postoperative day 2 the
patients started to receive oral amiodarone 600 mg per day three
times a day for 5 days, 400 mg per day twice a day for the
following 5 day-period, and 200 mg per day in a single dose for the
last 20 days for a total of 30 days. For patients randomized to the
control arm, a 5% glucose infusion was given intravenously for the
first 48 hours. The patients were then switched to oral placebo in
the same manner as the amiodarone group. To avoid an increased
incidence of AF as a result of -blocker withdrawal, -blockers
were continued in patients who were receiving -blockers at the
time of the surgery, if possible.
Operative Techniques
All operations were performed through a median sternotomy.
Cardiopulmonary bypass (CPB) was established via standard aor-
tocaval cannulation with a roller pump and hollow-fiber membrane
oxygenator at moderate hypothermia (28°C to 30°C), with pump
flow rates of 2.0 to 2.5 L.min1.m2 to maintain a perfusion
pressure of about 65 mm Hg. During bypass the hematocrit value
was maintained between 20% and 25%. After aortic crossclamp-
ing, all patients received intermittent cold blood cardioplegia.
Cardioplegic solution was delivered either in an antegrade fashion
via the aortic root or in a retrograde fashion via the coronary sinus.
Topical hypothermia with cold saline solution was used in all
operations. Distal anastomoses were performed during a period of
aortic crossclamping and proximal anastomoses were performed
with partial aortic clamping during rewarming. Conduits for by-
pass included saphenous veins or internal thoracic arteries or a
combination of the two.
Postoperative Monitoring
After surgery, all patients were admitted to the cardiovascular
surgical ICU and monitored continuously with electrocardiogra-
phy, three-channel pressure, and cardiac output via pulmonary
artery catheter. When the patients were transferred to wards,
continuous electrocardiographic tracings were recorded until hos-
pital discharge. Twelve-lead electrocardiograms was done rou-
tinely every day and additionally when an arrhythmia was detected
during the hospital stay to confirm and document any rhythm
disturbances. QTC intervals were measured by the use of the
Bazett formula. Postoperative AF was defined as atrial activity that
was either not discernible or completely unorganized, accompa-
nied by an irregular ventricular rate lasting more than 5 minutes or
requiring therapy as a result of hemodynamic compromise. Man-
agement of AF was directed by the cardiac surgery team. We
began oral anticoagulation with warfarin when the arrhythmia was
persistent for more than 24 hours. At the end of the prophylactic
oral amiodarone therapy (postoperative day 30), all patients were
clinically examined and a 12-lead electrocardiogram was obtained.
Intraoperative and postoperative data, including complications and
adverse events, were assessed through a medical record review.
Statistical Analysis
Statistical analysis was performed with the Statistical Package for
Social Sciences (SPSS Inc, Chicago, Ill). Where appropriate, data
are expressed as mean values  standard deviation or as percent-
ages. Once the homogeneity was confirmed with the Levene test,
independent-samples t test was used to compare the noncategorical
or continuous variables. Comparison between groups for categor-
ical variables was made by the 2 test and Fisher exact test was
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used if expected contingency table cell frequencies were less than
5.
Results
Baseline Characteristics
Of the 157 patients enrolled in this study, 77 were random-
ized to receive amiodarone, whereas 80 were randomized to
receive placebo. The mean age of the patients was 59.3 
8.9 years in the amiodarone group and 61.1  9.6 years in
the control group (P .212). The patient demographics and
preoperative variables are summarized in Table 1 and were
not significantly different. Prevalence of coexisting disor-
ders and coronary risk factors such as hypertension, diabetes
mellitus, and hyperlipidemia in both groups of patients was
similar (Table 2).
Operative Variables
Operative variables are summarized in Table 3. There were
no significant differences in CPB time, crossclamp time,
number of grafts, and intraoperative hemodynamic vari-
ables.
Postoperative AF
The incidence of new-onset AF occurring during hospital-
ization was 10.4% (8 patients) in the amiodarone group and
25.0% (20 patients) in the control group (P  .017). AF
occurred at a mean of 1.9  0.6 days after surgery in the
amiodarone group and 2.5  1.3 days after surgery in the
control group (P  .239). The maximum ventricular rate
during AF was significantly lower in the amiodarone group
than in the control group (105.9  19.1 vs 126.0  18.5
beats/min, P  .016). There was significant difference be-
tween the groups in the duration of AF (12.8 4.8 hours vs
34.7  28.7 hours, P  .003). In the amiodarone group, AF
converted to sinus rhythm spontaneously in 4 patients. In
the remaining patients, 2 treated successfully with
-blocker, 1 with digoxin, and the last 1 with electrical
cardioversion. In the control group, AF converted to sinus
rhythm spontaneously in 1 patient. Among the other 19
patients, 7 patients were managed with amiodarone, 5 with
digoxin, 2 with calcium-channel blockers, 1 with -blocker,
and 4 with electrical cardioversion. One patient in the ami-
odarone group had symptomatic AF within 3 weeks of
discharge, whereas 4 patients (5.0%) in the control group
had symptomatic AF in the same period (P  .367).
Postoperative Complications
Postoperative complications other than rhythm disturbances
occurred in 32 patients (16 in the amiodarone group and 16
in the control group, P  .904). Postoperative complica-
tions and results are shown in Table 4. There was no
significant difference in the incidence of low cardiac output,
cerebrovascular accident, respiratory complication, or renal
dysfunction. More rhythm disturbances such as ventricular
fibrillation or ventricular arrhythmia were detected in the
control group (18.8% vs 7.8%, P  .044).
Amiodarone had to be discontinued in 4 patients (5.2%)
because of sinus bradycardia (heart rate less than 60 beats/
min) or excessive corrected QT interval prolongation (440
TABLE 1. Patients demographics and preoperative vari-
ables (mean  SD)
Amiodarone
group, n (%)
Control group,
n (%)
Statistical
significance
Patient number 77 80
Sex .313*
Male 62 (80.5) 59 (73.7)
Female 15 (19.5) 21 (26.3)
Age (years) 59.3 8.9 61.1 9.6 .212†
BSA (m2) 1.83 0.19 1.81 0.16 .388†
LVEF (%) 47.0 9.9 47.9 10.4 .554†
LVEF 30 (%) 8 (10.4) 7 (8.8) .727*
AST level (IU/L) 22.7 9.9 24.6 13.0 .318†
ALT level (IU/L) 25.9 14.7 29.9 18.6 .133†
Preoperative
medication
-blockers 23 (29.9) 17 (21.3) .215*
Ca-channel
blockers
24 (31.2) 24 (30.0) .874†
Digitalis 5 (6.5) 4 (5.0) .743‡
BSA, body surface area; LVEF, left ventricular ejection fraction; AST,
aspartate aminotransferase; ALT, alanine aminotransferase.
*Chi-square test.
†Independent samples Student t test.
‡Fisher’s exact test.
TABLE 2. Associated coexisting disorders and coronary
risk factors
Amiodarone
group, n (%)
Control group,
n (%)
Statistical
significance
Hypertension 39 (50.6) 52 (65.0) .069*
Smoking 45 (61.9) 15 (65.2) .820*
DM 20 (26.0) 25 (31.3) .465*
Hyperlipidemia 39 (50.6) 45 (56.3) .482*
History of CHF 14 (18.2) 13 (16.3) .748*
Prior MI 32 (41.6) 41 (51.3) .224*
PVD 4 (5.2) 9 (11.3) .169*
CVD 2 (2.6) 2 (2.5) 1.0†
NYHA class 2.40 0.65 2.44 0.55 .717‡
Unstable angina pectoris 12 (15.6) 14 (17.5) .747*
Coronary artery lesion
No. of vessels 2.71 0.51 2.79 0.47 .350‡
3-vessel disease 57 (74.0) 65 (81.3) .272*
LMC disease 7 (9.1) 9 (11.3) .655*
DM, diabetes mellitus; CHF, congestive heart failure; MI, myocardial in-
farction; PVD, peripheral vascular disease; CVD, cerebrovascular disease;
NYHA, New York Heart Association; LMC, left main coronary artery.
*Chi-square test.
†Fisher’s exact test.
‡Independent samples Student t test.
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ms). In these patients bradycardia resolved after discontin-
uation of amiodarone, and AF did not occur in any of them.
In comparison, 2 patients (2.5%) in control group had
significant bradycardia (P  .437). Additionally, a higher
incidence of postoperative hypotension was observed in
patients receiving amiodarone (10.4% vs 5.0%), but this did
not reach statistical significance. No patients in the amio-
darone group had other significant side effects or adverse
reactions included pulmonary toxicity during the study.
Nausea was the most frequent side effect in the amiodarone
group, which did not require the discontinuation of the
amiodarone. -Blockers were discontinued in 3 (3.9%) of
the amiodarone group patients and in 2 (2.5%) of control
group patients (P  .677). In all patients the reason of
discontinuation was low cardiac output.
The average length of in-hospital stay for patients in
amiodarone group was 6.8 1.7 days, whereas it was 7.8
2.9 days for patients in control group (P .014). There was
one postoperative death (1.3%) in amiodarone group. The
cause of death was cerebrovascular accident in a patient
who did not have AF. There were 3 postoperative deaths in
control group. AF occurred in 2 of them. The causes of
deaths in control group patients were ventricular tachyar-
rhythmia in 2 patients and low cardiac output in 1 patient.
Discussion
Despite the advances in surgical technique and myocardial
protection, the incidence of AF has not been decreased after
cardiac surgery, especially in elderly patients.17,18 Advances
in continuous monitoring technology have led to more fre-
quent diagnosis of AF. Our results confirm the high inci-
dence of AF in patients who had CABG. AF has been
thought of as transient and benign, but it can lead to hemo-
dynamic instability or peripheral embolization. Postopera-
tive AF is a widely known risk factor for postoperative
stroke.19
It appears that there are multiple underlying pathophys-
iologic mechanisms responsible for the high incidence of
postoperative AF. Preoperative factors such as an increased
age, hypertension, chronic obstructive pulmonary disease,
greater number of grafts, poor left ventricular function,
preoperative -blocker withdrawal, and history of AF were
identified as predictors of AF.5,20,21 Previous studies have
indicated that AF after CABG is associated with sympa-
thetic activity.22 Pericardial inflammation or effusion has
been detected after cardiac surgery before AF develops.23
The incidence of postoperative atrial arrhythmia was found
to be higher in patients with a history of paroxysmal AF.24
A combination of the factors outlined above might be im-
portant in the occurrence of AF.
Although long-term sequelae of postoperative AF are
unusual, the frequent consequence is prolonged hospitaliza-
tion and increased medical costs. Therefore, any interven-
tion that would reduce the incidence of postoperative AF
would result in an economic benefit. A variety of pharma-
cologic strategies are available to prevent AF after cardiac
surgery. However, controversies still continue about the
risks and benefits of these strategies.
The principles of treatment for postoperative AF are the
control of the ventricular rate, anticoagulation, and conver-
TABLE 3. Operative variables (mean  SD)
Amiodarone
group, n (%)
Control group,
n (%)
Statistical
significance
CPB (min) 65.1 18.3 69.7 21.7 .156*
Crossclamp time (min) 41.0 13.4 44.0 14.8 .192*
Graft number 2.99 0.75 3.02 0.71 .745*
Use of LITA 75 (97.4) 77 (96.3) 1.0†
Mediastinal drainage (mL) 619 233 564 305 .098*
Post-CPB
Pacing 3 (3.9) 2 (2.5) .677‡
Electrolyte imbalance 23 (29.9) 25 (31.3) .851*
Heart rate (bpm) 102.2 16.9 99.4 15.1 .281*
CI (L/min.m2) 2.99 0.7 2.95 0.72 .744*
Body temperature (°C) 35.0 0.8 34.8 0.9 .129*
Use of IABP 0 1 (1.3) 1.0†
Perioperative MI 2 (2.6) 3 (3.8) 1.0†
Perioperative hypotension 13 (16.9) 11 (13.8) .586‡
CPB, cardiopulmonary bypass; LITA, left internal thoracic artery; CI, car-
diac index; IABP, intraaortic balloon pump; MI, myocardinal infarction.
*Independent samples Student t test.
†Fisher’s exact test.
‡Chi-square test.
TABLE 4. Postoperative complications and results
Amiodarone
group, n (%)
Control group,
n (%)
Statistical
significance
In-hospital morbidity 16 (20.8) 16 (20.0) .904*
Acute renal failure 3 (3.9) 1 (1.3) .361†
Low cardiac output 9 (11.7) 9 (11.3) .931*
Pulmonary complications 2 (2.6) 2 (2.5) 1.0†
Wound infection 4 (5.2) 3 (3.8) .716†
Sepsis and MOF 1 (1.3) 1 (1.3) 1.0†
Gastrointestinal bleeding 1 (1.3) 1 (1.3) 1.0†
Stroke 1 (1.3) 0 .490†
Transient neurologic deficit 1 (1.3) 4 (5.0) .367†
Reexploration for bleeding 1 (1.3) 3 (3.8) .620†
Ventricular tachyarrhythmia 6 (7.8) 15 (18.8) .044*
Postoperative continuation of
-blockers 31 (40.3) 30 (37.5) .723*
Ca-channel blockers 14 (18.2) 20 (25.0) .300*
Digitalis 7 (9.1) 12 (15.0) .256*
Entubation (hours) 13.6 3.4 15.3 15.1 .330‡
ICU stay (days) 1.25 0.65 1.20 0.77 .682‡
In-hospital stay (days) 6.8 1.7 7.8 2.9 .014‡
In-hospital mortality 1 (1.3) 3 (3.8) .620†
MOF, multiple organ failure; ICU, intensive care unit.
*Chi-square test.
†Fisher’s exact test.
‡Independent sample Student t test.
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sion to sinus rhythm. Amiodarone increases the refractory
period of atrial and ventricular muscle as well as the atrio-
ventricular node. It has mild -blocker and calcium channel
blocker activity in addition to its class III antiarrhythmic
activity. It has been effective in acute as well as chronic
AF.25 As a result of these properties, amiodarone has been
studied in the prevention of AF after cardiac operations.26-30
Use of oral amiodarone preoperatively and/or postopera-
tively was investigated in some of these studies.17,25,29,31
Others have used postoperative intravenous amioda-
rone.10,32,33 In most of these studies, amiodarone adminis-
tration ranged from 2 to 15 days. After short-term low-dose
intravenous administration, AF tended to occur after termi-
nation of the infusion.21,33 There is no consensus about the
optimal dose of amiodarone. In most of the studies, intra-
venous amiodarone doses ranged from 10 to 20 mg/kg per
day over 2 to 8 days.10,16,21,26,28,32,33 Oral amiodarone doses
ranged from 2.8 to 7.0 g over 7 to 20 days.17,25,27,29-31 A
limited number of trials used a combination of intravenous
and oral amiodarone.16,28 The variability in dosing strategy
and the inconsistency in results have led us to adopt a new
regimen. We used a combination of postoperative intrave-
nous amiodarone after oral administration for two reasons:
first, to take the advantage of accelerated loading time with
the intravenous amiodarone, and second, to obtain the in-
cremental benefits of the oral amiodarone over the short-
term intravenous administration. To prevent the possible
adverse effects such as hypotension or bradycardia, we have
used relatively short-term low-dose (10 mg/kg per day for
48 hours) intravenous administration followed by oral ta-
pered doses at a total of 9.0 g over 30 days. We have used
a dosing strategy that gives higher total dose by increasing
the length of oral administration instead of giving it at a
relatively high dose in a short hospitalization period.
Our study showed that in CABG patients amiodarone in
the immediate postoperative period effectively reduced the
incidence of postoperative AF by more than 50%. Among
the patients who did have AF, amiodarone reduced the
ventricular rate significantly. The duration of AF was also
longer in control group patients. Postoperative AF is often a
transient phenomenon. AF persisted in only 2 patients de-
spite repetitive attempts at restoring sinus rhythm even with
electrical cardioversion.
We also investigated the effect of amiodarone prophy-
laxis on the length of ICU and in-hospital stay. The length
of hospitalization was significantly reduced from 7.8 to 6.8
days. This can be explained by increased duration of AF in
control group patients. We found that amiodarone prophy-
laxis is cost-effective even it only reduces the length of stay
by 1 day. In our protocol, total cost of amiodarone is only
one third that of the cost of 1-day hospitalization.
In the present study, development of AF did not produce
significant increases in the length of ICU stay. AF occurred
mostly after postoperative day 2, when the patients have
already left the ICU. In our practice, new-onset AF without
hemodynamic compromise is not an indication for readmis-
sion to ICU. In addition to the lower incidence of postop-
erative AF, the amiodarone group patients had significantly
less postoperative ventricular arrhythmias than the control
group. Fatal ventricular tachyarrhythmia was not seen in the
amiodarone group, whereas 2 deaths in the control group
related to ventricular tachyarrhythmia. These results may be
due to its effectiveness against a broad range of arrhythmias.
Accordingly, large randomized trials indicate that amioda-
rone is a potent suppressor of ventricular arrhythmia and
reduces arrhythmic death after myocardial infarction.34,35
Patients whose -blocker therapy is discontinued postoper-
atively have a higher incidence of postoperative atrial tachy-
arrhythmias.36 In the present study, patients who had been
receiving -blockers before surgery continued to receive
them, if possible, postoperatively. One of the drawbacks of
our study is that the number of study patients (approximate-
ly 26.0%) who received preoperative -blocking drugs is
limited. In our hospital, preoperative management was di-
rected by the patients’ cardiologist rather than by a stan-
dardized protocol. We think that possible negative impact of
this nonstandardized treatment have been compensated by
the randomization of patients. There is no difference in the
percentage of patients who were receiving -blockers be-
tween the groups in either the preoperative or the postop-
erative period.
Our homogenous patient population demonstrates the
efficacy and safety of a combination of intravenous and oral
amiodarone after CABG. The combined intravenous and
oral amiodarone regimen used in this study appears to be
well tolerated. Amiodarone was discontinued approxi-
mately 5% of our patients because of sinus bradycardia and
excessive QT prolongation. Additionally, a higher incidence
of postoperative hypotension that was observed in patients
receiving amiodarone (10.4% vs 5.0%) did not reach to
statistical significance. No proarrhythmic effect was ob-
served among the patients who received amiodarone. The
direct negative inotropic effect of the drug is minimal and
transient, may be partially caused by its antisympathetic
effect, and usually does not lead to a decreased cardiac
output.37 Amiodarone is well tolerated in patients with poor
left ventricular function and can be used for patients who
are not candidates for -blockade. The group of patients
with left ventricular ejection fraction less than 30% repre-
sents a small percentage (10%) in our study population. Our
primary aim was not to investigate the effect of amiodarone
in patients with poor left ventricular function. Our results
may not be applicable to the cohort of patients with a lower
ejection fraction.
In conclusion, we showed that postoperative intravenous
amiodarone followed by oral administration significantly
Cardiopulmonary Support and Physiology Yagdi et al
1424 The Journal of Thoracic and Cardiovascular Surgery ● June 2003
CSP
reduced the incidence of new-onset postoperative AF with-
out an increase in adverse effects. It also reduced the ven-
tricular rate and the duration of AF, as well as the length of
hospital stay.
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